MSTN and sarcopenia: As many therapeutical approaches fail to improve muscular strength and function (e.g., some MSTN inhibitors), researchers have seriously considered other drugs that simulate the effects of physical activity on activated protein kinase (AMPK) signaling as attractive targets for sarcopenia, for example, metformin, a common type II diabetes treatment.